DK1716233T3 - Reguleret stopkodongennemlæsning - Google Patents

Reguleret stopkodongennemlæsning

Info

Publication number
DK1716233T3
DK1716233T3 DK05700620T DK05700620T DK1716233T3 DK 1716233 T3 DK1716233 T3 DK 1716233T3 DK 05700620 T DK05700620 T DK 05700620T DK 05700620 T DK05700620 T DK 05700620T DK 1716233 T3 DK1716233 T3 DK 1716233T3
Authority
DK
Denmark
Prior art keywords
polypeptide
stop codon
interest
cells expressing
cells
Prior art date
Application number
DK05700620T
Other languages
Danish (da)
English (en)
Inventor
Thomas Bouquin
Original Assignee
Maxygen Holdings Ltd
Maxygen Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34830514&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1716233(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Maxygen Holdings Ltd, Maxygen Aps filed Critical Maxygen Holdings Ltd
Application granted granted Critical
Publication of DK1716233T3 publication Critical patent/DK1716233T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
DK05700620T 2004-01-30 2005-01-28 Reguleret stopkodongennemlæsning DK1716233T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54082004P 2004-01-30 2004-01-30
US63130604P 2004-11-29 2004-11-29
PCT/DK2005/000070 WO2005073375A1 (fr) 2004-01-30 2005-01-28 Translecture regulee d'un codon d'arret

Publications (1)

Publication Number Publication Date
DK1716233T3 true DK1716233T3 (da) 2009-10-26

Family

ID=34830514

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05700620T DK1716233T3 (da) 2004-01-30 2005-01-28 Reguleret stopkodongennemlæsning

Country Status (7)

Country Link
US (1) US20070224635A1 (fr)
EP (1) EP1716233B1 (fr)
AT (1) ATE440949T1 (fr)
DE (1) DE602005016218D1 (fr)
DK (1) DK1716233T3 (fr)
ES (1) ES2329807T3 (fr)
WO (1) WO2005073375A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006132925A2 (fr) 2005-06-01 2006-12-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Procede de biosynthese de peptide amide et administration d'endomorphine-2 in vivo en vue du traitement de la douleur
US20090304641A1 (en) * 2005-10-17 2009-12-10 Children's Hospital Boston Methods and Compositions for Regulating Gene Expression
CA2734340C (fr) * 2008-08-28 2019-03-05 Novartis Ag Presentation sur la surface cellulaire d'isoformes de polypeptide par lecture de codon stop
JP2012501192A (ja) * 2008-09-02 2012-01-19 ルピン・リミテッド 組換え体の同定、選択および発現のためのベクター
EP2401377B1 (fr) 2009-02-27 2016-05-18 Novartis AG Système de vecteurs d'expression comprenant deux marqueurs de sélection
WO2011140529A1 (fr) * 2010-05-07 2011-11-10 Lakepharma, Inc. Marqueurs de surface et leurs utilisations pour génération rapide de lignée cellulaire stable et amplification génique
JP2013528374A (ja) 2010-05-10 2013-07-11 パーシード セラピューティクス リミテッド ライアビリティ カンパニー Ｖｌａ４のポリペプチド阻害剤
WO2012019168A2 (fr) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Acides nucléiques modifiés et leurs procédés d'utilisation
CA2821992A1 (fr) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Synthese d'acides nucleiques et methodes d'utilisation associees
CA2831613A1 (fr) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Administration et formulation d'acides nucleiques genetiquement modifies
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2911677T3 (es) 2011-10-03 2022-05-20 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
DE12858350T1 (de) 2011-12-16 2021-10-07 Modernatx, Inc. Modifizierte mrna zusammensetzungen
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP3501550A1 (fr) 2012-04-02 2019-06-26 Moderna Therapeutics, Inc. Polynucléotides modifiés pour la production de protéines associées à une maladie humaine
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
WO2014058982A2 (fr) * 2012-10-10 2014-04-17 Temple University Of The Commonwealth System Of Higher Education Biocapteurs de facteur nucléaire 2 apparenté au facteur érythroïde 2 (nrf2) et modulateurs de nrf2
US20150267209A1 (en) * 2012-10-22 2015-09-24 Life Technologies Corporation System and Method for Visualization of Optimized Protein Expression
PT2922962T (pt) 2012-11-20 2017-03-29 Novartis Ag Cassete de expressão optimizada para expressão de um polipéptido com elevado rendimento
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
EP3382026B1 (fr) * 2012-11-30 2021-01-06 Larix Biosciences LLC Nouveau procédé de dépistage de lignées cellulaires
WO2014141037A1 (fr) 2013-03-11 2014-09-18 Novartis Ag Procédé de recherche systématique de clones de cellules
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2991679A4 (fr) 2013-04-29 2016-12-07 Adimab Llc Réactifs multispécificité, procédés de préparation et d'utilisation associés
AU2014297966B2 (en) 2013-07-31 2017-10-26 Novartis Ag Novel selection vectors and methods of selecting eukaryotic host cells
EP3052521A1 (fr) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucléotides codant pour un récepteur de lipoprotéines de faible densité
US11242551B2 (en) 2013-12-20 2022-02-08 Novartis Ag Eukaryotic cells and methods for recombinantly expressing a product of interest
SG11201604215XA (en) 2013-12-20 2016-07-28 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
TWI664190B (zh) * 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264341A (en) * 1989-08-30 1993-11-23 Eli Lilly And Company Selective cloning for high monoclonal antibody secreting hybridomas
WO1994005781A1 (fr) * 1992-09-04 1994-03-17 The Scripps Research Institute Phagemides coexprimant un recepteur de surface et une proteine heterologue de surface
US6458538B1 (en) * 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
US20020086427A1 (en) * 2000-03-23 2002-07-04 Leiden Jeffrey M. Inducible eukaryotic expression system that regulates protein translation
DE10053224A1 (de) * 2000-10-26 2002-05-08 Univ Goettingen Georg August Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
JP2004532636A (ja) * 2001-05-21 2004-10-28 インヴィトロジェン コーポレーション 核酸分子の単離に用いるための組成物および方法
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US20060099673A1 (en) * 2001-08-02 2006-05-11 Hansjorg Hauser Novel recombinant gene expression method by stop codon suppression
EP1298207B2 (fr) * 2001-10-01 2015-12-30 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Méthodes pour construire des banques de protéines et pour isoler des protéines de ces banques
US20040101823A1 (en) * 2001-12-21 2004-05-27 Maxygen, Inc. HIV-1 viral variants for improved animal models of HIV-1 pathogenesis
US7833741B2 (en) * 2002-08-07 2010-11-16 Ambit Biosciences Corporation Uncoupling of DNA insert propagation and expression of protein for phage display
WO2004106375A1 (fr) * 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Banque de fab pour la preparation de fab anti-vegf et antirabique

Also Published As

Publication number Publication date
EP1716233B1 (fr) 2009-08-26
WO2005073375A1 (fr) 2005-08-11
ATE440949T1 (de) 2009-09-15
DE602005016218D1 (de) 2009-10-08
US20070224635A1 (en) 2007-09-27
EP1716233A1 (fr) 2006-11-02
ES2329807T3 (es) 2009-12-01

Similar Documents

Publication Publication Date Title
DK1716233T3 (da) Reguleret stopkodongennemlæsning
Kaisermann et al. Fungal communities are more sensitive indicators to non-extreme soil moisture variations than bacterial communities
WO2005020924A3 (fr) Moyen rapide permettant d'obtenir des clones a haute expression de cellules mammaliennes, selon un procede de criblage par methylcellulose et immunoprecipitation
WO2007047578A3 (fr) Affichage cellulaire de libraires d'anticorps
Hermanns et al. Primary human coculture model of alveolo-capillary unit to study mechanisms of injury to peripheral lung
MX2012009175A (es) Metodos para identificar y aislar celulas que expresan un polipeptido.
WO2009023184A3 (fr) Bibliothèques universelles de domaines de liaison de la fibronectine de type iii
MX2020009907A (es) Glicoformas afucosiladas totales de anticuerpos producidos en cultivo celular.
DK1812046T3 (da) Melanocortinreceptor-bindende mimetilegemer, sammensætninger, fremgangsmåder og anvendelser
WO2007055823A3 (fr) Lignees cellulaires et anticorps exprimant le gpcr
EA200800996A1 (ru) Способ получения т-клеточной популяции
DK1379671T3 (da) Fremgangsmåder til dyrkning af circovirus
RU2010129550A (ru) Органические соединения
CY1111769T1 (el) Παρασκευη κυτταρων
Brauer et al. MMP-19 deficiency causes aggravation of colitis due to defects in innate immune cell function
ATE546531T1 (de) Transaktivierungssystem für säugerzellen
WO2004111194A3 (fr) Procede d'accroissement de la production en culture de proteines
DE602006015826D1 (de) T zur messung translationaler rückcodierung
JP2016506239A5 (fr)
WO2007005611A3 (fr) Cellules progenitrices et leurs utilisations
ATE525467T1 (de) Auswahl synthetischer gene mit guter expression
Boucher et al. Logging-induced edge and configuration of old-growth forest remnants in the eastern North American boreal forests
SI2084529T1 (sl) Stabilne celične linije in postopki za evaluacijo gastrointestinalne absorpcije kemikalij
Pinna et al. The Mediterranean bioconstructor Lithophyllum stictiforme shows adaptability to future warming
WO2024086617A3 (fr) Anticorps anti-cd3 dépendant du ph et procédés associés